From Tier Table Database
CDC Office of Public Health Genomics (OPHG) conducts horizon scanning (a systematic research method to find and follow novel technologies appearing in the literature) to identify and track the progress of genomic tests as they move from research into clinical and public health practice. As an aid in organizing horizon scanning results, OPHG ranks genomic tests, and family health history applications, by levels of evidence. See detail.
| Disease/Disorder | Test or Application | Intended Use | Tier Classified | Detail |
|---|---|---|---|---|
| Cystic fibrosis (CF) | CFTR (detection of F508del homozygousity) | Pharmacogenomic for ivacaftor and lumacaftor combination | Tier 1  | |
| Hypertrophic cardiomyopathy (HCM) - symptoms and signs of disease suggesting specific causes of HCM | Genetic testing (including analysis of most frequently implicated sarcomere protein genes) | Confirm diagnosis of HCM | Tier 1 | |
| Hypertrophic cardiomyopathy (HCM) | Genetic testing (including analysis of most frequently implicated sarcomere protein genes) | Enable cascade screening of relatives | Tier 1 | |
| Hypertrophic cardiomyopathy (HCM) that cannot be explained solely by non-genetic cause | Genetic counseling | Help patients understand and manage HCM | Tier 1 | |
| Hereditary hemochromatosis | HFE | Population screening | Tier 3 |
No hay comentarios:
Publicar un comentario